Intravenous Vistide data

An interim analysis of Vistide iv in the first 60 of 126 patients showed that the drug delayed the time to progression in patients with relapsing CMV retinitis.

In the multicenter, dose-comparison trial, patients were randomized to one of two Vistide maintenance treatment programs. Both groups received initial treatment of 5mg/kg iv once per week for two weeks, followed by one of two maintenance doses - 5 or 3 mg/kg - given once every other week. ...